- Home
- GAME vs VERU Comparison
GAME vs VERU Comparison
Compare GAME & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- VERU
- Stock Information
- Founded
- GAME 2011
- VERU 1971
- Country
- GAME United States
- VERU United States
- Employees
- GAME N/A
- VERU N/A
- Industry
- GAME
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- GAME
- VERU Health Care
- Exchange
- GAME Nasdaq
- VERU Nasdaq
- Market Cap
- GAME 68.2M
- VERU 54.6M
- IPO Year
- GAME 2009
- VERU 1990
- Fundamental
- Price
- GAME $0.47
- VERU $2.52
- Analyst Decision
- GAME
- VERU Strong Buy
- Analyst Count
- GAME 0
- VERU 2
- Target Price
- GAME N/A
- VERU $25.00
- AVG Volume (30 Days)
- GAME 1.8M
- VERU 193.7K
- Earning Date
- GAME 11-13-2025
- VERU 12-15-2025
- Dividend Yield
- GAME N/A
- VERU N/A
- EPS Growth
- GAME N/A
- VERU N/A
- EPS
- GAME N/A
- VERU N/A
- Revenue
- GAME $102,810,388.00
- VERU $16,886,419.00
- Revenue This Year
- GAME $2.32
- VERU N/A
- Revenue Next Year
- GAME $26.42
- VERU N/A
- P/E Ratio
- GAME N/A
- VERU N/A
- Revenue Growth
- GAME 36.23
- VERU 337.24
- 52 Week Low
- GAME $0.44
- VERU $2.42
- 52 Week High
- GAME $2.87
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- GAME 31.91
- VERU 31.02
- Support Level
- GAME $0.44
- VERU $2.50
- Resistance Level
- GAME $0.55
- VERU $2.86
- Average True Range (ATR)
- GAME 0.05
- VERU 0.23
- MACD
- GAME -0.01
- VERU -0.04
- Stochastic Oscillator
- GAME 11.10
- VERU 4.53
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.